Comparison of AMG and EMG to Avoid Residual Paralysis After General Anesthesia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

214 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates three different neuromuscular monitoring devices (acceleromyography, one- or three-dimensional, and electromyography) with regard to their precision to detect residual paralysis after injection of neuromuscular blocking agents and recurrence of paralysis after administration of reversal agents in a clinical setting.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Automatic Periodic Stimulation and Continuous Electromyography (EMG) for Facial Nerve Monitoring During Parotidectomy

NCT03172520

Parotid Gland Disorders

TERMINATED NA

Algorithm of Muscle Function Tests to Detect Residual Neuromuscular Blockade.

NCT03219138

Postoperative Residual Curarization

COMPLETED NA

Evaluation of the Tof Cuff for Perioperative Neuromuscular Transmission

NCT03117387

Neuromuscular Blockade

COMPLETED

Comparison of Acceleromyography and Electromyography in Obese Patients Undergoing General Anesthesia

NCT07283354

Obesity

NOT_YET_RECRUITING

Predicting Neuromuscular Recovery in Surgical Patients Using Machine Learning

NCT05471882

Residual Paralysis, Post Anesthesia Postoperative Complications Neuromuscular Blockade +1 more

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neuromuscular blocking agents (NMBAs) are routinely used as standard part of a modern, balanced anesthesia regime. A residual duration of action exceeding the end of surgery, also called residual neuromuscular paralysis, is a common undesired side effect and increases the risk for postoperative pulmonary complications such as aspiration or pneumonia delaying patients' discharge from the post-anesthesia care unit. To limit the incidence of residual paralysis in daily anesthesia care, quantitative neuromuscular monitoring is recommended after injection of NMBAs. If a residual effect of a NMBA is detected at the end of surgery, reversal agents such as cholinesterase inhibitors, e.g. neostigmine or a selective relaxant binding agent, e.g. sugammadex can be administered. However, if reversal agents are not adequately dosed, the risk for a residual neuromuscular blockade re-occurs. Accordingly, neuromuscular monitoring is also useful to control the action of the administered reversal agents.

Although several techniques of neuromuscular monitoring are established in clinical practice, electromyography (EMG) and acceleromyography (AMG) are the most common quantitative neuromuscular monitoring devices. Electromyography, the gold standard for detecting residual neuromuscular block, is based on measuring summarized spikes of evoked muscle contractions. Acceleromyography measuring the acceleration of evoked muscle contraction is also commercially available and easy to use. This acceleration, however, can be measured both one-dimensionally and three-dimensionally.

This study evaluates the three described neuromuscular monitoring devices with regard to their precision to detect residual paralysis after administration of NMBAs and recurrence of neuromuscular blockade after administration of reversal agents in a clinical setting. We plan to include and randomize a total of 200 patients. The study participants will be recruited from patients scheduled for surgery at the Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. In each patient, acceleromyography (either one- or three-dimensional) will be compared with the calibrated electromyography. The findings will help to indicate which neuromuscular monitoring device is most suitable for detecting residual paralysis and recurrent neuromuscular blockade.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Observation of Neuromuscular Block Respiratory Paralysis Anaesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AMG (one-dimensionally) versus EMG

Neuromuscular monitoring in patients scheduled for surgery under general anesthesia

Group Type EXPERIMENTAL

Acceleromyography (AMG, one-dimensionally)

Intervention Type DEVICE

Neuromuscular monitoring

Electromyography (EMG)

Intervention Type DEVICE

Neuromuscular monitoring

AMG (three-dimensionally) versus EMG

Neuromuscular monitoring in patients scheduled for surgery under general anesthesia

Group Type EXPERIMENTAL

Acceleromyography (AMG, three-dimensionally)

Intervention Type DEVICE

Neuromuscular monitoring

Electromyography (EMG)

Intervention Type DEVICE

Neuromuscular monitoring

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acceleromyography (AMG, one-dimensionally)

Neuromuscular monitoring

Intervention Type DEVICE

Acceleromyography (AMG, three-dimensionally)

Neuromuscular monitoring

Intervention Type DEVICE

Electromyography (EMG)

Neuromuscular monitoring

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients ASA physical status I-III
* Patients older than 18 years
* General anesthesia with the use of the neuromuscular blocking agent rocuronium
* Expected duration of surgery more than 2 hours
* Patients having given informed consent to the study

Exclusion Criteria

* Known or suspected allergy towards anesthetics/sugammadex or rocuronium
* Pregnant and breastfeeding women
* Known or suspected neuromuscular disease (Multiple sclerosis, myasthenia gravis)
* Anatomic and functional malformations with expected difficult intubation
* body mass index \>35kg/m2
* Contraindication for the use of rocuronium or sugammadex
* Malignant hyperthermia
* Patients with a legal guardian

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No